Big pharma, Partnering, Pharma

Cerecor gains rights to KOR antagonist from Lilly

Posted on 23 February 2015

Tags: , ,

Cerecor has acquired exclusive, worldwide rights from Eli Lilly to develop and commercialize LY2456302 (which will be designated as CERC-501), a Phase 2-ready, potent and selective kappa opioid receptor (KOR) antagonist.

KORs are believed to play a key role in modulating stress, mood and addictive disorders.

Research also suggests that selective KOR antagonists can block both the physical and emotional symptoms of nicotine withdrawal.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of CERC-501.

License consideration includes undisclosed milestone payments and royalties.

Cerecor anticipates completing the technology transfer activities by mid-2015 and initiating clinical trials in the second-half of the year.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply